RTX001 Autologous Engineered Macrophages for Liver Cirrhosis

Phase 1

Recruiting

• Conditions: End-stage Liver Disease (ESLD); Cirrhosis, Liver; Cirrhosis, Decompensated; Liver Diseases; Fibrosis and Cirrhosis of Liver; Decompensated Liver Cirrhosis; Decompensated Cirrhosis; Steatotic Liver Disease
• Interventions: Drug: RTX001

• Registration Number: NCT06823713
• Lead Sponsor: Resolution Therapeutics Limited

Brief Summary

The purpose of this study is to assess the safety and efficacy of RTX001 in patients with end-stage liver disease. This study is the first time RTX001, a macrophage cell therapy engineered to have an anti-inflammatory and anti-fibrotic effect, will be given to humans.

Detailed Description

EMERALD is a first-in-human Phase 1/2 open label study designed to evaluate the safety, tolerability and efficacy of RTX001 in patients with end-stage liver disease who have recovered from a recent hepatic decompensation (first within the past 6 months).

RTX001 is an autologous engineered macrophage cell therapy. It is made from a person's own cells. It uses a type of white blood cell called macrophages. These cells have been found to help improve liver function in participants with liver cirrhosis.

To produce RTX001, each study participant must first undergo steps that will allow us to collect white blood cells using a process called leukapheresis. Leukapheresis is a procedure in which white blood cells are separated from the collected blood using a specific machine. The collected white blood cells are sent to a manufacturing facility to make RTX001. As RTX001 is an autologous product, this means that it can only be given back to the same participant who donated the cells. The term "autologous macrophage" used in the study title refers to white blood cells (macrophages) coming from the same person's body (autologous).

The data in this study will be compared to the external control data from a Natural History Study called OPAL (NCT06380335) which is being conducted in a similar participant population from primarily the same study sites in the United Kingdom (UK) and EU.

Study Timeline

• Study Start: 2024-10-15
• Study First Submitted: 2024-11-06
• Study First Submitted QC: 2025-02-06
• Study First Posted: 2025-02-12
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-09
• Last Update Posted: 2025-04-10
• Primary Completion: 2028-08-29
• Study Completion: 2028-11-29

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. Male or female age ≥18-75 years.

2. Patient is willing and able to provide informed consent to participate in the study.

3. Patient confirms willingness/ability to comply with all study procedures.

4. Diagnosis of liver cirrhosis based on at least one of:

   1. Clinical and radiological features that correlate with a diagnosis of cirrhosis.
   2. Transient elastography (Fibroscan) >15 kPa.
   3. Previous liver biopsy confirming histological features of cirrhosis.

5. Aetiology of liver disease of steatotic liver disease including MASLD or Met-ALD or ALD a. Hospitalised as an inpatient for a recent major hepatic decompensation event including ascites, hepatic encephalopathy, variceal bleed, HRS-AKI or SBP, this being the only hospitalisation for an hepatic decompensation event hospitalisation within the last 6 months, and where recent is defined as within 6 weeks of hospital discharge.

6. Hospitalised as an inpatient for a recent major hepatic decompensation event including ascites, hepatic encephalopathy, variceal bleed, HRS-AKI or SBP, this being the only hospitalisation for an hepatic decompensation event hospitalisation within the last 6 months, and where recent is defined as within 6 weeks of hospital discharge.

7. Outpatient: Medically refractory ascites (ONLY), that recurs (i.e., second therapeutic LVP) within a 6-month period. Medically refractory ascites is defined by the repeated (≥2) need for LVP (i.e., therapeutic, not diagnostic) at least once per 8 weeks despite best medical attempts to control the ascites by sodium restriction and diuretic treatment, as confirmed by the Investigator. Onset is defined as the date of the second therapeutic LVP.

8. Confirmatory PEth alcohol test <200 ng/ml 8. MELD score of 12-20 taken within two weeks of 'qualifying' decompensation event.

Participants are excluded from the study if any of the following criteria apply:

Exclusion Criteria

1. Liver cirrhosis due to:

   1. any viral hepatitidies, or
   2. autoimmune and cholestatic aetiologies including, but not limited to, primary biliary cholangitis and primary sclerosing cholangitis.

2. Acute liver disease in the absence of underlying liver cirrhosis, including, but not limited to, drug induced liver injury.

3. Any current organ failure requiring more than outpatient supportive care, and not associated with the participant's qualifying hepatic decompensation event.

4. Known splenomegaly ≥16 cm.

5. Thrombocytopenia <50×109/L.

6. Presence or suspicion of any of the following co-morbidities:

   1. History of liver transplantation or other organ transplant.
   2. ACLF.
   3. Sepsis (with positive microbial cultures) or as defined by the Principal Investigator, unless stable and is at least 4 weeks after having completed a full course of IV antibiotics.
   4. Known human immunodeficiency virus.
   5. Known syphilis.
   6. Known human T-lymphotropic virus 1.
   7. Pulmonary embolism.
   8. Hepatocellular carcinoma, or any active malignant disease within the last five years, (excluding non-melanoma skin cancer, cervical carcinoma in situ, superficial bladder cancer, benign polyps etc.).
   9. Co-hepatic morbidities e.g., portal vein thrombosis.
   10. Participants with hepatic hydrothorax are excluded unless it is a small hydrothorax, not clinically apparent, that is detected incidentally by radiologic evaluation that does not require clinical intervention.
   11. Chronic renal impairment (on dialysis) or unresolved AKI.
   12. Acute or chronic heart failure (New York Heart Association Grade III/IV).
   13. Porto-pulmonary hypertension.
   14. Severe chronic lung disease e.g., chronic obstructive pulmonary disease or interstitial lung disease where the forced expiratory volume in the first second (FEV1) is less than 50% and/or FEV1/forced vital capacity is less than 60%.
   15. Hepatopulmonary syndrome.
   16. Previous or current treatment with multiple infusions of albumin for therapeutic intent. [Use of albumin infusion at the time of large volume paracentesis for circulatory support is allowed.]
   17. Significant untreated/unstable psychiatric disease.
   18. Transjugular intrahepatic portosystemic shunt (TIPSS).

7. As judged by the Investigator, any evidence of intercurrent illness that is either life threatening or of clinical significance such that it might limit compliance with study procedures.

8. Alcohol misuse in the period between identification of the participant as potentially suitable for this study to Screening (Visit 1), defined as alcohol intake greater than three units/day for females and four units/day for males, or binge drinking (>14 units/day) as determined by the Investigator. N.B. One unit is equivalent to 14 g of alcohol: a half-pint (~240 mL) of beer, one glass (125 mL) of wine or one (25 mL) measure of spirits.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
RTX001	RTX001	Following the manufacture of RTX001, participants will be assigned into one of two groups based on the compensation status of their cirrhosis at this time as follows: * Stabilised Group: Participants who remain clinically stable, as assessed by the Investigator, since their qualifying decompensation event. * Subsequent Decompensation Group: Participants who have had a further decompensation event following their leukapheresis and/or the RTX001 manufacturing process. Treatment will be identical for both groups, and each participant will receive a maximum of four doses of RTX001 by intravenous infusion Patients in the Subsequent Decompensation Group need to have stabilised before receiving treatment.

Primary Outcome Measures

Name	Time	Method
Safety and Tolerability	At each infusion; day of infusion up to two weeks post-infusion	Incidence and severity of infusion reactions

Secondary Outcome Measures

Name	Time	Method
Time to clinical event	2.5 years	Time to clinical event, defined as all hepatic decompensation events including SBP and/or HRS-AKI, new listing for liver transplantation, liver transplantation, or death.
Time to mortality	2.5 years	Time-to all-cause mortality (hepatic related and all-cause).
Change in Model for End Stage Liver Disease score 3.0 (MELD3.0)	2.5 years	To evaluate changes in Model for End Stage Liver Disease (MELD3.0) scores, from baseline to end of study in the Stabilised Group participants.

Trial Locations

Locations (9)

Hospital Universitario Reina Sofía; 🇪🇸 Córdoba, Spain

Hospital General Universitario Gregorio Marañon; 🇪🇸 Madrid, Spain

Bristol Royal Infirmary; 🇬🇧 Bristol, United Kingdom

Royal Infirmary of Edinburgh; 🇬🇧 Edinburgh, United Kingdom

Royal Liverpool University Hospital; 🇬🇧 Liverpool, United Kingdom

King's College Hospital; 🇬🇧 London, United Kingdom

St George's Hospital; 🇬🇧 London, United Kingdom

St Mary's Hospital; 🇬🇧 London, United Kingdom

Nottingham University Hospital; 🇬🇧 Nottingham, United Kingdom